Pharmacokinetics of sepantronium bromide (YM155), a small-molecule suppressor of survivin, in Japanese patients with advanced solid tumors: Dose proportionality and influence of renal impairment

Cancer Chemotherapy and Pharmacology

Volumn 70, Issue 3, 2012, Pages 373-380

  Aoyama, Yumiko ^a   Nishimura, Tetsuya ^a   Sawamoto, Taiji ^a   Satoh, Taroh ^b   Katashima, Masataka ^a   Nakagawa, Kazuhiko ^c  

^a ASTELLAS PHARMA INC   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c KINKI UNIVERSITY   (Japan)

Author keywords

Advanced solid tumor; Pharmacokinetics; Renal impairment; Sepantronium bromide; YM155

Indexed keywords

SEPANTRONIUM BROMIDE;

ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARTICLE; CASTRATION RESISTANT PROSTATE CANCER; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; LIMIT OF QUANTITATION; LUNG NON SMALL CELL CANCER; MALE; MELANOMA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SOLID TUMOR;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; CLINICAL TRIALS, PHASE I AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMIDAZOLES; INFUSIONS, INTRAVENOUS; INHIBITOR OF APOPTOSIS PROTEINS; JAPAN; MALE; MIDDLE AGED; NAPHTHOQUINONES; NEOPLASMS; RENAL INSUFFICIENCY; RETROSPECTIVE STUDIES; SEX FACTORS;

EID: 84866390931     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-012-1913-z     Document Type: Article

References (18)

1. Nakahara T, Takeuchi M, Kinoyama I et al (2007) YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res 67:8014-8021 (Pubitemid 47395135)
2. Nakahara T, Kita A, Yamanaka K et al (2011) Broad spectrum and potent antitumor activities of YM155, a novel small-molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models. Cancer Sci 102:614-621
3. Nakahara T, Yamanaka K, Hatakeyama S et al (2011) YM155, a novel survivin suppressant, enhances taxane-induced apoptosis and tumor regression in a human Calu 6 lung cancer xenograft model. Anticancer Drugs 22:454-462
4. Kita A, Nakahara T, Yamanaka K et al (2011) Antitumor effects of YM155, a novel survivin suppressant, against human aggressive non-Hodgkin lymphoma. Leukemia Res 35:787-792
5. Giaccone G, Zatloukal P, Roubec J et al (2009) Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer. J Clin Oncol 27:4481-4486
6. Karavasilis V, Mita A, Hudes G et al (2007) Phase II monotherapy study of YM155, a novel survivin suppressant, administered by 168-hour continuous infusion in previously treated hormone refractory prostate cancer (HRPC). J Clin Oncol 25(June 20 Supplement):5135
7. Lewis KD, Samlowski W, Ward J et al (2011) A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma. Invest New Drugs 29:161-166
8. Cheson BD, Vose JM, Bartlett NL et al (2009) Safety and efficacy of YM155 in diffuse large B-cell lymphoma (DLBCL). J Clin Oncol 27(Supple):8502
9. Tolcher AW, Papadopoulos K, Patnaik A et al (2009) Phase I/II open-label study of YM155 plus docetaxel and prednisone in men with hormone refractory prostate cancer (HRPC). ASCO genitourinary cancers symposium abstract, p 214
10. Kelly RJ, Rajan A, Chun G, Lopez-Chavez A, Giaccone G (2011) A phase 1 study of paclitaxel, carboplatin, and YM155 (survivin suppressor) in subjects with solid tumors. J Clin Oncol 29(Supple): 3090
11. Satoh T, Okamoto I, Miyazaki M et al (2009) Phase I study of YM155, a novel survivin suppressant, in patients with advanced solid tumors. Clin Cancer Res 15:3872-3880
12. Sohda K, Suzuki K, Nakamura E et al (2007) Metabolism of YM155 monobromide, a novel survivin suppressant: in vitro species comparison and identification of metabolites in rats. Drug Metab Rev 39(Supple 1):253
13. Tolcher AW, Mita A, Lewis LD et al (2008) Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin. J Clin Oncol 26:5198-5203
14. National Kidney Foundation (2002) K/DOQI Clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 39(2 Suppl 1):S1-266 (also available at: http://www.kidney.org/ Professionals/Kdoqi/guidelines-ckd/toc.htm)
15. Japanese Society of Nephrology (2009) Evidence-based practice guideline for the treatment of CKD. Clin Exp Nephrol 13:537-566
16. Nolin TD, Naud J, Leblond FA, Pichette V (2008) Emerging evidence of the impact of kidney disease on drug metabolism and transport. Clin Pharmacol Ther 83:898-903 (Pubitemid 351704931)
17. Huang SM, Temple R, Xiao S, Zhang L, Lesko LJ (2009) When to conduct a renal impairment study during drug development: US Food and Drug Administration perspective. Clin Pharmacol Ther 86:475-479
18. Iwai M, Minematsu T, Narikawa S, Usui T, Kamimura H (2009) Involvement of human organic cation transporter 1 in the hepatic uptake of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2- ylmethyl)-4,9-dihydro-1H- naphtho[2,3-d]imidazolium bromide (YM155 monobromide), a novel, small molecule survivin suppressant. Drug Metab Dispos 37:1856-1863